Actively Recruiting
Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-03-31
60
Participants Needed
1
Research Sites
265 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of the study is to determine whether the use of the CEST sequence would have diagnostic performance equivalent to the reference method of T2\* infusion with contrast injection in the diagnosis of radionecrosis of lung cancer brain metastases.
CONDITIONS
Official Title
Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients older than 18 years
- Histologically confirmed primary lung cancer
- Brain metastases confirmed or suspected
- Metastases treated with radiotherapy
- Receiving treatment for brain metastases including stereotactic or gamma-knife radiotherapy
- Evidence of lesion growth on follow-up MRI
- Affiliated with a social security scheme
You will not qualify if you...
- Refusal to participate in the study
- Contraindications to MRI
- Patient refuses imaging
- Patient with state medical aid (unless exempted from affiliation)
- Severe cognitive impairment preventing informed consent
- Patients under guardianship or deprived of liberty
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hôpital Bichat-Claude Bernard
Paris, France, 75018
Actively Recruiting
Research Team
A
Augustin Gaudemer, MD
CONTACT
M
Marie-Cécile Henry-Feugeas, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here